Nurix Therapeutics (NRIX) Retained Earnings (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Retained Earnings for 8 consecutive years, with -$1.2 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Retained Earnings fell 40.71% year-over-year to -$1.2 billion; the TTM figure through May 2026 stood at -$1.2 billion (down 40.71% YoY), while the FY2025 annual figure was $105000.0, down 30.0% from the prior year.
• Retained Earnings slipped to -$1.2 billion in Q2 2026 per NRIX's latest filing, from -$1.1 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $150000.0 in Q4 2024 and bottomed at -$1.2 billion in Q2 2026.
• Historically, Retained Earnings has averaged -$436.3 million across 5 years, with a median of -$454.1 million in 2023.
• Annual changes were most pronounced in 2024 — Retained Earnings jumped 100.03% — and 2025, when it plunged 227071.43%.
• Nurix Therapeutics' Retained Earnings stood at -$401.3 million in 2022, then slumped by 35.87% to -$545.2 million in 2023, then soared by 100.03% to $150000.0 in 2024, then fell by 30.0% to $105000.0 in 2025, then sank by 1123847.62% to -$1.2 billion in 2026.
• Business Quant data shows NRIX's Retained Earnings at -$1.2 billion in Q2 2026, -$1.1 billion in Q1 2026, and $105000.0 in Q4 2025.